Re-irradiation using proton therapy for radiation-induced secondary cancer with Li-Fraumeni syndrome: A case report and review of literature.
Chemoradiotherapy, Adjuvant
/ adverse effects
Child
Female
Histiocytoma, Benign Fibrous
/ diagnosis
Humans
Li-Fraumeni Syndrome
/ diagnosis
Magnetic Resonance Imaging
Neoplasm Recurrence, Local
/ diagnosis
Neoplasms, Radiation-Induced
/ diagnosis
Osteosarcoma
/ diagnosis
Positron-Emission Tomography
Proton Therapy
Re-Irradiation
/ methods
Rhabdomyosarcoma
/ therapy
Treatment Outcome
Li-Fraumeni syndrome
pediatric
proton radiotherapy
proton therapy
secondary cancer
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
Historique:
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
24
8
2021
Statut:
ppublish
Résumé
Li-Fraumeni syndrome (LFS) is a genetic disease that is hypersensitive to radiotherapy. Proton therapy (PT) was strongly recommended for pediatric and radiation-sensitive tumors. However, there is little information on PT for LFS. The patient was a 7-year-old girl with LFS who was diagnosed with radiation-induced right shoulder blade osteosarcoma and left chest wall malignant fibrous histiocytoma. Both tumors were in the area that had previously been irradiated (36-45 Gy by photon radiotherapy). Sixty-six GyE in 30 fractions was planned for both tumors. We set the clinical target to the minimum gross tumor volume. To comprehensively assess any adverse events, PT was conducted under hospital administration. Cisplatin was used as simultaneous combination chemotherapy. Although administration of granulocyte-colony stimulating factor was necessary for myelosuppression by chemotherapy, PT was completed without interruption. Acute radiation toxicity was observed as Grade 1 dermatitis. The dermatitis became exacerbated 2 weeks after PT but subsequently improved with conservation treatment alone. Twenty-three months after PT, magnetic resonance imaging showed an increase in the tumor on the right shoulder. A histological examination was not conducted as the family declined, but secondary cancer was suggested rather than recurrent osteosarcoma, as the tumor developed mainly from the soft tissue. Additional surgical treatment and radiotherapy were not indicated, and the patient died of tumor progression and sepsis caused by myelosuppression 27 months after undergoing PT. Up to 23 months after PT, there were no signs of Grade 2 or more late toxicities. This represents the first reported case of PT for a patient with LF to treat radiation-induced secondary cancer.
Identifiants
pubmed: 33342824
pii: JCanResTher_2020_16_6_1524_300998
doi: 10.4103/jcrt.JCRT_449_19
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1524-1527Déclaration de conflit d'intérêts
None